$377 Million is the total value of Cormorant Asset Management, LP's 54 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS | $14,892,000 | +20.5% | 1,168,000 | 0.0% | 3.95% | +38.9% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $14,701,000 | +6.0% | 100,000 | 0.0% | 3.90% | +22.2% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $13,695,000 | -36.6% | 207,500 | 0.0% | 3.63% | -27.0% | |
| TSRO | TESARO INC | $9,333,000 | +5.5% | 300,000 | 0.0% | 2.47% | +21.6% | |
| CMRX | CHIMERIX INC | $6,582,000 | -3.9% | 300,000 | 0.0% | 1.74% | +10.7% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $5,836,000 | +12.7% | 200,000 | 0.0% | 1.55% | +29.8% | |
| EGRX | EAGLE PHARMACEUTICALS INC | $5,732,000 | +12.4% | 400,000 | 0.0% | 1.52% | +29.5% | |
| RMTI | ROCKWELL MED INC | $4,796,000 | -5.3% | 400,000 | 0.0% | 1.27% | +9.2% | |
| REPH | RECRO PHARMA INC | $4,005,000 | +9.4% | 500,000 | 0.0% | 1.06% | +26.0% | |
| GNVC | GENVEC INC | $3,416,000 | -3.0% | 1,329,300 | 0.0% | 0.90% | +11.7% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $3,159,000 | -5.9% | 50,000 | 0.0% | 0.84% | +8.4% | |
| ASPX | AUSPEX PHARMACEUTICALS INC | $2,227,000 | -27.6% | 100,000 | 0.0% | 0.59% | -16.5% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,608,000 | -10.9% | 200,000 | 0.0% | 0.43% | +2.7% | |
| CLTX | CELSUS THERAPEUTICS PLCsponsored adr ne | $639,000 | -4.3% | 103,000 | 0.0% | 0.17% | +9.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.